Plasma procurement and plasma product safety in light of the COVID-19 pandemic from the perspective of the plasma industry.

ABSTRACT: This review, written from the perspective of the plasma industry, discusses plasma procurement and plasma product safety in light of the COVID-19 pandemic. The COVID-19 pandemic impacted the whole world and, therefore, not unexpectedly, the pharmaceutical industry too. In spite of this, the plasma protein industry has continued to provide life saving therapies to critically ill patients. Moreover, companies have collected COVID convalescent plasma (CP) to support development of investigational therapies, for example, hyperimmune globulins to potentially treat SARS-CoV-2 infection, and collaborated with those collecting COVID CP for direct transfusion, which has been made available under emergency use in the United States. For plasma that is fractionated to become a therapy, general knowled

SUBMITTER: Turecek PL 

PROVIDER: S-EPMC9115499 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature